Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today reported its financial results for the third quarter ended September 30, 2025.

Danaher and Shanghai Shangsi Institute of Natural Sciences signed a strategic cooperation memorandum On November 5, Danaher and Shanghai Shangsi Institute of Natural Sciences signed a stra..

2.4.3 Positive Guidance of Domestic Academic Environment The Chinese Society of Laboratory Medicine, China Society of medical laboratory equipment, and Chinese Medical Doctor Association Laboratory Doctor Branch..

OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended September 30, 2025.

Revvity, Inc. (NYSE: RVTY), today announced it has entered into a definitive agreement to acquire ACD/Labs, a global provider of scientific software solutions that support analytical characterization and molecular design across pharmaceutical and material sciences end markets. This acquisition expands the breadth and depth of Revvity Signals¡¯ solutions for bridging the gap between analytical data and actionable insights, further strengthening its ability to accelerate scientific innovation. The transaction is expected to close late in Q4 2025.

Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced financial results for the third quarter ended September 30, 2025.

Siemens Healthineers AG today announces its results for the fourth quarter of fiscal year 2025 ended September 30, 2025, and the full fiscal year 2025.

The Board of Directors of Diasorin S.p.A. (FTSE MIB: DIA), examined and approved the Group¡¯s Consolidated Financial Statements as of September 30, 2025.

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its fiscal 2025 fourth quarter and full year, which ended September 30, 2025.

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter ended September 30, 2025.

Original from: QuidelOrtho Third Quarter 2025 Results (all comparisons are to the prior year period) ¡¤ Total revenue was $700 million, as reported -..

Original from: bioM¨¦rieux ¡¤ 7.3% organic sales growth in the first nine months of the year, fully in line with annual guidance, with sales reaching a total of €2,992m, primarily driven by a 9% organic ..

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it has entered into a definitive agreement to fully acquire Parse Biosciences, a leading provider of scalable, instrument-free solutions for single-cell research.

BD (Becton, Dickinson and Company) (NYSE: BDX) a leading global medical technology company, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance and Conformit¨¦ Europ¨¦enne (CE) marking in the European Union for its Enteric Bacterial Panel* (EBP) and Enteric Bacterial Panel plus* (EBP plus) for the BD COR™ System.

The U.S. Food and Drug Administration ("FDA") has granted QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho"), a global leader of in vitro diagnostics, 510(k) clearance for the VITROS hs Troponin I Reagent Pack (the "VITROS hs Troponin I Assay"). The assay is intended for the quantitative measurement of cardiac troponin I (cTnI) in human plasma (heparin) to aid in the diagnosis of myocardial infarction (MI).